EU wants forcing manufacturers remove preinstalled mobile apps - Europe will require manufacturers to remove applications that they pre-install on the devices they assemble, be they mobile phones or computers. This is what emerges from an early draft of the new standard of Digital Services on which the Union works, and which will include a "black list" of behaviors that will be vetoed for technological ones.
The regulation will not go ahead until the end of this year, although some major technologies have already taken measures to prevent it.
The Financial Times has had access to this draft which, among other proposals, also includes the requirement for big tech companies to share data with their smaller rivals.
Pre-installed applications have been a constant for years, both in the smartphone market and in the market of large technological devices, such as computers themselves. Some manufacturers and even operators pre-install on mobile phones that offer their customers their own apps that are then impossible to remove.
This is the case of companies such as Samsung or Xiaomi, among others, that mount their terminals on an Android operating system to which they add a custom layer. In the case of Samsung, this layer is known as one UI. In the case of the Chinese firm, it is known as MIUI.
The problem is that, as a rule, these layers include their own apps that users cannot remove from their devices. At most, these apps can be disabled and hidden in some folder on your phone. Among the preinstalled apps of Xiaomi is its own Browser, its own app to consult the email, or an application in which you can install custom themes for the mobile.
However, phones with Google services can also bring pre-installed— or downloadable-the Google Chrome browser or Gmail app to check email. This hopelessly implies that many terminals come into the hands of their users with duplicities in their applications.
EU wants forcing manufacturers remove preinstalled mobile apps
All this is part of the draft of the new Digital Services Law on which the European Commission is working, and the draft of which has been accessed by the Financial Times. In an article this Wednesday, the economic newspaper details that big tech companies will be barred from giving preferential treatment to some apps or services over others, and will not be able to pre-install their apps or force other companies to pre-install their programs on their devices.
Other media such as Slash Gear that also echo this draft regulation detail that this new regulatory obligation could cause more than a headache to the technological, since many of these preinstalled apps are, in fact, included in the heart of the code of their layer on Android.
Although preinstalled apps were a much bigger problem when most mobile devices had limited storage-nowadays the weight of these apps on terminals is ridiculous - the European Union wants to give users more control over the technological devices they use.
End of the EU wants forcing manufacturers remove preinstalled mobile apps
Monoclonal antibody treatments: the possible solution to prevent coronavirus before the vaccine arrives
Laboratories have been trying to find a cure for coronavirus since the first outbreak and have not yet succeeded. At the moment, the only thing that can be done is to comply with the recommendations of the authorities: safety distance, mask, etc. but there could be a solution very soon.
Some manufacturers of vaccines against COVID-19 are in the final stages of clinical trials, but not all scientists have focused on this solution: some have tried to use existing medicines to treat the disease and others have instead decided to develop new and specific ones.
The latter is the case with monoclonal antibody treatments, which consist of synthetic copies of a specific antibody found in the blood of a person who has recovered from COVID-19, the BBC reports.
As the health Web explains, when a virus overcomes the body's initial defenses, a more specific response is activated and cells are produced that attack the invader. By recognizing it, they adhere to it and prevent it from spreading. Monoclonal antibodies, grown in bioreactor deposits, are copies of these natural proteins.
This type of solution is used to treat other diseases, including some types of cancer, and is given intravenously.
Although these antibodies dissipate after a while, this type of medication could temporarily prevent infection of people at risk, such as medical workers and the elderly. The safety risks of this type of cure are low, but there is concern that the virus may become resistant to specific antibodies, depending on health.
Regeneron is one of the pharmaceutical companies that are testing this type of coronavirus drug and this Tuesday published the results on patients who had been treated at home and not in the hospital.
The sample consisted of 275 people, of whom one third received placebo, another third received a high dose of the drug, and the remainder received a low dose. The researchers found antibodies in 45% of the patients, while another 41% did not develop any and 14% had no conclusive results.
The company has not published the full study and the press release does not make it clear which antibodies were being tested. According to the BGR website, Regeneron intends to discuss with the authorities soon the approval of the treatment so that it goes on the market as soon as possible
In addition, GlaxoSmithKline and Vir Biotechnology have also initiated trials in 1,300 high-risk patients in different parts of the world and will focus on preventing hospitalization of people with mild symptoms, according to Finanzas.com. The same media says that the results will be published before the end of the year.